Joinn Laboratories(China)Co.Ltd Past Earnings Performance
Past criteria checks 0/6
Joinn Laboratories(China)Co.Ltd has been growing earnings at an average annual rate of 10.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 26% per year.
Key information
10.2%
Earnings growth rate
7.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 26.0% |
| Return on equity | -0.1% |
| Net Margin | -0.04% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Joinn Laboratories(China)Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,125 | -1 | 332 | 90 |
| 30 Jun 24 | 2,214 | 137 | 323 | 88 |
| 31 Mar 24 | 2,332 | -63 | 313 | 92 |
| 31 Dec 23 | 2,376 | 397 | 315 | 97 |
| 30 Sep 23 | 2,579 | 770 | 311 | 106 |
| 30 Jun 23 | 2,503 | 794 | 316 | 109 |
| 31 Mar 23 | 2,366 | 1,137 | 324 | 93 |
| 31 Dec 22 | 2,268 | 1,074 | 310 | 78 |
| 30 Sep 22 | 1,936 | 941 | 316 | 63 |
| 30 Jun 22 | 1,759 | 775 | 297 | 51 |
| 31 Mar 22 | 1,587 | 589 | 270 | 50 |
| 31 Dec 21 | 1,517 | 557 | 273 | 48 |
| 30 Sep 21 | 1,301 | 419 | 278 | 37 |
| 30 Jun 21 | 1,213 | 379 | 261 | 44 |
| 31 Mar 21 | 1,122 | 389 | 243 | 49 |
| 31 Dec 20 | 1,076 | 315 | 219 | 51 |
| 30 Sep 20 | 922 | 253 | 182 | 62 |
| 30 Jun 20 | 836 | 237 | 159 | 52 |
| 31 Mar 20 | 720 | 194 | 138 | 44 |
| 31 Dec 19 | 639 | 187 | 113 | 40 |
| 30 Sep 19 | 513 | 128 | 106 | 32 |
| 30 Jun 19 | 475 | 126 | 97 | 29 |
| 31 Mar 19 | 432 | 112 | 91 | 25 |
| 31 Dec 18 | 409 | 108 | 85 | 24 |
| 30 Sep 18 | 375 | 99 | 76 | 25 |
| 30 Jun 18 | 341 | 87 | 57 | 36 |
| 31 Mar 18 | 334 | 92 | 56 | 31 |
| 31 Dec 17 | 301 | 76 | 59 | 26 |
| 30 Sep 17 | 294 | 74 | 59 | 19 |
| 31 Dec 16 | 242 | 52 | 66 | 0 |
| 31 Dec 15 | 207 | 49 | 56 | 0 |
| 31 Dec 14 | 185 | 49 | 45 | 0 |
| 31 Dec 13 | 144 | 22 | 43 | 0 |
Quality Earnings: 603127 is currently unprofitable.
Growing Profit Margin: 603127 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603127 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 603127's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603127 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.4%).
Return on Equity
High ROE: 603127 has a negative Return on Equity (-0.11%), as it is currently unprofitable.